States should take appropriate steps to ensure the effectiveness of domestic judicial mechanisms when addressing business-related human rights abuses, including considering ways to reduce legal, practical and other relevant barriers that could lead to a denial of access to remedy.6
As will be seen below there are numerous of such barriers facing individual plaintiffs.
In this contribution I will concentrate on civil law (tort) remedies and leave aside remedies under criminal law. The exercise of civil law remedies may not only result in compensation for the victims of corporate misconduct but will also hopefully help to prevent repetition of such misconduct. It may also achieve what the UN Human Rights Council has so far failed to do; clarify the content of the required standard of corporate conduct. Civil law remedies against multinational corporations may be exercised either in the host state or in the corporation's home state. If abuses have occurred in the host state, remedies should preferably be exercised there. However, victims in these states often "have no available cause of action, or face insurmountable obstacles to bringing their claims."7 It then makes sense if victims have access to remedies in the home state of the multinational corporation. This has been termed transnational human rights litigation.8
There is a widespread assumption among both legal scholars and human rights activists that transnational human rights litigation in response to extraterritorial corporate abuses depends on a single piece of United States legislation, the Alien Tort Statute (ATS).9 According to this school of thought, the Supreme Court's 2013 Kiobel judgment10 has interpreted the ATS in such a way that it has dealt a serious blow to the victims of corporate abuse and their lawyers because 
